Blog

Dec 9, 2024, 17:55

Shahrin Ahmed: The treatment of multiple myeloma is being improved

Shahrin Ahmed, Medical Specialist oncology at Canadian Cancer Society and Associate Professor at Staffordshire University, shared a post on X:

“The treatment of multiple myeloma is being improved –

The number of hematological malignancies globally with multiple myeloma (MM) is the second most frequent. While the disease is known for its aggressiveness and death, recent advances in treatment have significantly improved patient outcomes.

Proteasome inhibitors like bortezomib, carfilzomib, ixazomib, and monoclonal antibodies have all been developed to provide innovative therapies with fewer side effects over the past decade. Immunomodulators like thalidomide, lenalidomide, doxorubidomide, and corticosteroids like dexamethasone are some of the options available, including daratumumab, isatuximab, and elotuzumab.

These agents have been shown to improve efficacy when combined in regimens that target multiple pathways simultaneously.

By targeting myeloma cells more precisely, these therapies can improve patient quality of life, prolong remission, and delay disease progression. Through drug development and combination treatments, the potential for a cure is highlighted due to the evolution of MM therapies.

In 2022, according to global statistics from IARC and WHO, In 2023, there was an increase in diagnoses by 187,952 and deaths by 121,388 due to MM.

In 2023, statistical data from the United States indicates that men are more likely to experience migraines, both in terms of incidence and mortality. The disease caused approximately 2,000 more deaths than women, and men made up more than 50% of the 35,730 new cases reported that year.

Developing therapeutic strategies for multiple myeloma, emphasizing the shift from conventional treatments to novel targeted therapies. Combining advances in drug development, genetic insights, and supportive care.

These innovations have impacted patient management and outcomes, with the objective of enhancing treatment protocols and paving the way for a potential cure highlighted in the study.

Patient survival and quality of life have been significantly improved due to remarkable advancements in the treatment landscape for multiple myeloma (MM).

Disease management has undergone a transformation with the use of targeted therapies and combination regimens, such as lenalidomide, carfilzomib, and bendamustine, that provide greater and sustained results while minimizing side effects.

Maintenance strategies post-transplantation have become more reliant on these therapies that have prolonged progression-free survival.”

Shahrin Ahmed

More posts featuring Shahrin Ahmed.

and bendamustine Bortezomib Canadian Cancer Society cancer Cancer Research UK CancerAwareness CancerTreatment Carfilzomib corticosteroids Daratumumab dexamethasone disease Disease Management doxorubidomide drug development elotuzumab hematological IARC Immunomodulators Isatuximab ixazomib Lenalidomide Leukemia & Myeloma Congress lymphoma malignancies monoclonal antibodies multiple myeloma myeloma cells OncoDaily Oncology patient patient management Proteasome inhibitors Shahrin Ahmed Staffordshire University Supportive care Thalidomide therapies treatment United States WHO

Wanda Sykes and Breast Cancer: How She Went Against, How She Survived, and More

Highlights from Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer - Day 2

Highlights from Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer - Day 1

100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2024

Have faith in yourself, and look out for the bad man - reflections from Neil Ranasinghe's involvement in LGCW

Special Coverage